<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">F1000Res</journal-id>
<journal-id journal-id-type="iso-abbrev">F1000Res</journal-id>
<journal-id journal-id-type="pmc">F1000Research</journal-id>
<journal-title-group>
<journal-title>F1000Research</journal-title>
</journal-title-group>
<issn pub-type="epub">2046-1402</issn>
<publisher>
<publisher-name>F1000Research</publisher-name>
<publisher-loc>London, UK</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28721212</article-id>
<article-id pub-id-type="pmc">5497814</article-id>
<article-id pub-id-type="doi">10.12688/f1000research.11202.1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
<subj-group>
<subject>Articles</subject>
<subj-group>
<subject>Arrhythmias, Electrophysiology &amp; Pacing</subject>
</subj-group>
<subj-group>
<subject>Cardiovascular Imaging</subject>
</subj-group>
<subj-group>
<subject>Cardiovascular Pharmacology</subject>
</subj-group>
<subj-group>
<subject>Congenital Heart Disease</subject>
</subj-group>
<subj-group>
<subject>Heart Failure</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Recent advances in the management of ventricular tachyarrhythmias</article-title>
<fn-group content-type="pub-status">
<fn>
<p>[version 1; referees: 2 approved]</p>
</fn>
</fn-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Batul</surname>
<given-names>Syeda Atiqa</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Olshansky</surname>
<given-names>Brian</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fisher</surname>
<given-names>John D.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gopinathannair</surname>
<given-names>Rakesh</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4611-3687</contrib-id>
<xref ref-type="corresp" rid="c1">a</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<aff id="a1">
<label>1</label>Arrhythmia Division, Montefiore Medical Center, Bronx, New York, USA</aff>
<aff id="a2">
<label>2</label>University of Iowa Hospitals and Clinics, Iowa City, USA</aff>
<aff id="a3">
<label>3</label>Division of Cardiovascular Medicine, University of Louisville School of Medicine, Louisville, USA</aff>
</contrib-group>
<author-notes>
<corresp id="c1">
<label>a</label>
<email xlink:href="mailto:rakesh.gopinathannair@louisville.edu">rakesh.gopinathannair@louisville.edu</email>
</corresp>
<fn fn-type="con">
<p>SAB, BO, and JDF contributed to drafting and making critical revisions of the manuscript. RG contributed to supervision and to drafting and making critical revisions of the manuscript for key intellectual content.</p>
</fn>
<fn fn-type="COI-statement">
<p>
<bold>Competing interests: </bold>SAB declares that she has no competing interests. BO has served as a consultant to Daiichi-Sankyo, Biotronik, Cardionomics, BioControl, Amarin, Boehringer Ingelheim, On-X, Abbott Vascular, and Sanofi. JDF has served as a consultant to Medtronic and has received fellowship support from Medtronic, Boston Scientific, Biotronik, and St. Jude Medical. RG has served as a consultant to St. Jude Medical and served on speakers’ bureaus of the American Heart Association, Pfizer, Bristol-Myers Squibb, Zoll Medical, and AltaThera Pharmaceuticals and on an advisory board of HealthTrust PG.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>6</volume>
<elocation-id>1027</elocation-id>
<history>
<date date-type="accepted">
<day>26</day>
<month>6</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2017 Batul SA et al.</copyright-statement>
<copyright-year>2017</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="f1000research-6-12086.pdf" xlink:type="simple"></self-uri>
<abstract>
<p>Ventricular arrhythmias are an important cause of cardiovascular morbidity and mortality, particularly in those with structural heart disease, inherited cardiomyopathies, and channelopathies. The goals of ventricular arrhythmia management include symptom relief, improving quality of life, reducing implantable cardioverter defibrillator shocks, preventing deterioration of left ventricular function, reducing risk of arrhythmic death, and potentially improving overall survival. Guideline-directed medical therapy and implantable cardioverter defibrillator implantation remain the mainstay of therapy to prevent sudden cardiac death in patients with ventricular arrhythmias in the setting of structural heart disease. Recent advances in imaging modalities and commercial availability of genetic testing panels have enhanced our mechanistic understanding of the disease processes and, along with significant progress in catheter-based ablative therapies, have enabled a tailored and more effective management of drug-refractory ventricular arrhythmias. Several gaps in our knowledge remain and require further research. In this article, we review the recent advances in the diagnosis and management of ventricular arrhythmias.</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>Ventricular Arrhythmias</kwd>
<kwd>cardiomyopathy</kwd>
<kwd>catheter ablation</kwd>
<kwd>implantable cardioverter-defibrillator</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
</funding-group>
</article-meta>
<notes>
<sec sec-type="editor-note">
<title>Editorial Note on the Review Process</title>
<p>
<ext-link ext-link-type="uri" xlink:href="http://f1000research.com/browse/f1000-faculty-reviews">F1000 Faculty Reviews</ext-link> are commissioned from members of the prestigious
<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/thefaculty">F1000 Faculty</ext-link> and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).</p>
<p>The referees who approved this article are: </p>
<list list-content="reviewer-list" list-type="simple">
<list-item>
<p>
<named-content content-type="reviewer-name">Pasquale Santangeli</named-content>, Electrophysiology Section, Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, USA
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p>
</list-item>
<list-item>
<p>
<named-content content-type="reviewer-name">Lars Eckardt</named-content>, Division of Electrophysiology, Department of Cardiovascular Medicine, , University of Münster, Münster, Germany
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p>
</list-item>
</list>
</sec>
</notes>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Sudden cardiac death claims 350,000 to 400,000 lives annually in the US
<sup><xref ref-type="bibr" rid="ref-1">1</xref></sup>. Ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) accounts for 25 to 36% of witnessed cardiac arrests at home and 38 to 79% of witnessed cardiac arrests in public
<sup><xref ref-type="bibr" rid="ref-2">2</xref></sup>. Ventricular arrhythmias (VAs) represent a broad spectrum spanning single ectopic beats to sustained VT and VF. These arrhythmias encompass clinical conditions ranging from benign to life threatening. Sustained VAs are mostly associated with structural or ischemic heart disease (60 to 80%) followed by channelopathies and idiopathic VAs (VA in the absence of structural heart disease)
<sup><xref ref-type="bibr" rid="ref-3">3</xref>,
<xref ref-type="bibr" rid="ref-4">4</xref></sup>. Although life-threatening VAs are greatest in those with known coronary artery disease, myocardial infarction, and depressed ejection fraction, a considerable number of patients with non-ischemic cardiomyopathy (NICM) experience fatal events due to VT or VF as well
<sup><xref ref-type="bibr" rid="ref-5">5</xref></sup>.</p>
<p>Different forms of VAs can coexist in the same patient, can be isolated or frequent, and have differing mechanisms. Premature ventricular contractions are the most common and are generally considered benign. Non-sustained VT is at least three consecutive ventricular beats at a rate of at least 100 beats per minute; if VT exceeds 30 seconds or is hemodynamically unstable, it is considered “sustained”. VT can be regular or irregular in rate and morphology. Sustained monomorphic VT has the same activation sequence from beat to beat and generally occurs because of a stable re-entry circuit in patients with structural heart disease or because of automaticity in idiopathic VTs. The 12-lead electrocardiogram (ECG) provides an approximation of the exit site. On the other hand, polymorphic VT that often degenerates into VF is more often seen in acute myocardial ischemia or infarction as well as with several genetically mediated syndromes
<sup><xref ref-type="bibr" rid="ref-6">6</xref></sup>.</p>
<p>The goals of management of VAs include symptom relief (including syncope, worsening heart failure, and ischemic chest pain), improving quality of life, reducing implantable cardioverter defibrillator (ICD) shocks, preventing deterioration of left ventricular function, reducing risk of arrhythmic death, and improving overall survival
<sup><xref ref-type="bibr" rid="ref-7">7</xref>–
<xref ref-type="bibr" rid="ref-10">10</xref></sup>. Treatment of VAs should take into account the underlying medical conditions, the cardiac disorders, the presence of heart failure, the cause for the arrhythmias, consequences of the VAs, and the risks and benefits of the therapeutic pharmacological or invasive strategy
<sup><xref ref-type="bibr" rid="ref-6">6</xref>,
<xref ref-type="bibr" rid="ref-8">8</xref>,
<xref ref-type="bibr" rid="ref-9">9</xref></sup>.</p>
<p>ICDs are the mainstay of therapy to reduce the risk of sudden cardiac death due to VT and VF. Despite the mortality benefit gained from ICD therapy, electrical shocks from the device as well as unopposed and unnecessary right ventricular pacing should be monitored for and appropriately addressed
<sup><xref ref-type="bibr" rid="ref-7">7</xref>,
<xref ref-type="bibr" rid="ref-11">11</xref>–
<xref ref-type="bibr" rid="ref-13">13</xref></sup>. According to current data, both anti-arrhythmic drugs and catheter ablation may reduce the recurrence of VAs without offering any survival benefit
<sup><xref ref-type="bibr" rid="ref-10">10</xref></sup>. Recurrent ventricular tachyarrhythmias and ICD shocks are the major indication for anti-arrhythmic drug therapy, but these medications can also be pro-arrhythmic
<sup><xref ref-type="bibr" rid="ref-13">13</xref></sup>. Catheter ablation has evolved as a promising therapy to reduce the risk of VT recurrence; it is superior to medical therapy alone, according to clinical trials
<sup><xref ref-type="bibr" rid="ref-14">14</xref>–
<xref ref-type="bibr" rid="ref-16">16</xref></sup>. Despite improved mechanistic understanding and progress in catheter ablation technology that has led to effective treatment of focal and idiopathic VT, the long-term success rates for VT ablation remain modest in both ischemic and non-ischemic cardiomyopathies
<sup><xref ref-type="bibr" rid="ref-17">17</xref></sup>.</p>
<p>Considerable research and clinical effort in recent years have been focused on the development of diagnostic modalities and imaging tools to identify the arrhythmogenic substrate responsible for VT (focal or scar), genetic screening for markers of channelopathies, and superior mapping and ablation technologies. These advances have allowed us to tailor our approach to VA management on the basis of the underlying etiology with higher efficacy
<sup><xref ref-type="bibr" rid="ref-6">6</xref>,
<xref ref-type="bibr" rid="ref-8">8</xref>,
<xref ref-type="bibr" rid="ref-9">9</xref></sup>.</p>
<p>In this review, we aim to provide an update on the newer advances in the management of VAs.</p>
</sec>
<sec>
<title>Update on diagnostic and non-invasive imaging modalities</title>
<p>For over 100 years, cardiologists relied on the ECG, monitoring strategies, and limited intracardiac electrodes to diagnose VAs. With mechanisms of VT now better defined in structural heart disease, non-invasive imaging modalities—including echocardiography, cardiac computed tomography (CT), cardiac magnetic resonance imaging (MRI) (CMR), and nuclear studies—have become an integral part of the diagnostic and management strategy. The information derived from these tests not only is important to identify those with structural heart disease, assess left and right ventricular function, and risk-stratify those at highest risk of inducible VT/VF on the basis of scar size in order to select the patients who would derive the most benefit from an ICD but also serves as a guide for planning ablation procedures
<sup><xref ref-type="bibr" rid="ref-8">8</xref>,
<xref ref-type="bibr" rid="ref-18">18</xref>,
<xref ref-type="bibr" rid="ref-19">19</xref></sup>. The 2015 European Society of Cardiology Guidelines have extended a class IIa recommendation to perform CMR or CT in patients where echocardiography fails to provide accurate assessment of ventricular function or underlying structural changes that may be arrhythmogenic, such as the scar size, distribution, and transmurality
<sup><xref ref-type="bibr" rid="ref-8">8</xref></sup>.</p>
<p>Although there are no large randomized controlled trials, multiple small studies have reported a potential benefit of obtaining pre-procedural imaging such as delayed enhancement CMR (DE-MRI) and incorporating the information into intracardiac mapping systems
<sup><xref ref-type="bibr" rid="ref-20">20</xref></sup>. Piers
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-21">21</xref></sup> described the characteristics of critical isthmus sites in 44 patients with ischemic cardiomyopathy and NICM undergoing VT ablation with pre-procedural CMR. The authors found the critical VT isthmus sites to be in close proximity to areas of higher (&gt;75%) scar transmurality and scar border zones as noted in CMR.</p>
<p>Contrast-enhanced MRI- and CT-derived scar data have been shown to correlate well with electroanatomic mapping (EAM) reconstructions. In a recent study by Esposito
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-22">22</xref></sup>, CT with delayed enhancement provided a detailed three-dimensional (3D) scar characterization with good sensitivity (76%) and specificity (86%) and a very high negative predictive value (95%) when correlated with voltage on EAM. Whereas EAM may be unable to quantify the non-transmural parts of the scar, information obtained from pre-procedural CMR may help in these instances.</p>
<p>Substrate characterization with CMR is also very useful in hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular dysplasia (ARVD), and acquired immunological and inflammatory conditions (for example, sarcoidosis)
<sup><xref ref-type="bibr" rid="ref-22">22</xref>–
<xref ref-type="bibr" rid="ref-28">28</xref></sup>. A minority of patients with sustained left bundle branch block and inferior axis morphology VT, resembling idiopathic outflow tract VT, may have early concealed ARVD. CMR can help differentiate true idiopathic VT from early-stage ARVD or sarcoidosis and change the clinical approach for these patients
<sup><xref ref-type="bibr" rid="ref-29">29</xref></sup>. CMR may be of particular value in those with abnormal resting ECG (for example, right precordial T wave inversion in V1–V3).</p>
<p>Contrast CT has the added advantage of providing good visualization of coronary arteries. Lipomatous metaplasia (myocardial fat deposition) along with fibrosis in areas of chronic myocardial infarction has been observed in patients with ischemic heart disease on contrast CT and has been associated with fractionated electrograms and critical VT circuits
<sup><xref ref-type="bibr" rid="ref-30">30</xref></sup>. In patients with VT due to a local (myocarditis) or systemic (for example, sarcoidosis) inflammatory condition, fluorine-18 fluoro-2-deoxyglucose (18-FDG) positron emission tomography (PET/CT) can identify patients who may benefit from early immunosuppressive therapy versus catheter ablation
<sup><xref ref-type="bibr" rid="ref-31">31</xref></sup>.</p>
<p>The future of non-invasive mapping of VAs will focus on the creation of image-based simulation to estimate ablation targets in VAs, integration of multi-lead electrocardiography to construct computerized activation maps, and endo-epicardial and perhaps also mid-myocardial signal-intensity mapping that will identify the pathological substrates and VT exit sites which can be targeted more efficaciously
<sup><xref ref-type="bibr" rid="ref-32">32</xref>–
<xref ref-type="bibr" rid="ref-34">34</xref></sup>.</p>
</sec>
<sec>
<title>Advances in channelopathies and inherited cardiomyopathies</title>
<p>Up to half of the families of sudden cardiac arrest victims below 50 years of age are carriers of cardiac genetic channelopathies or hereditary cardiomyopathies. The 2015 Expert Consensus Statement from the Heart Rhythm Society recommends that patients and first-degree relatives with diagnosed or suspected inherited cardiovascular disease as a potential cause of sudden cardiac arrest be evaluated in a dedicated clinic with appropriately trained staff (class I)
<sup><xref ref-type="bibr" rid="ref-9">9</xref>,
<xref ref-type="bibr" rid="ref-35">35</xref></sup>.</p>
<p>Extended molecular gene panels now can be performed at appropriate centers at a low cost, allowing early identification of a channelopathy or inherited cardiomyopathy. This, in turn, allows risk stratification of sudden cardiac death and introduction of appropriately timed therapy (lifestyle changes, pharmacologic therapy versus ICD implantation or catheter ablation or both (
<xref ref-type="table" rid="T1">Table 1</xref>)
<sup><xref ref-type="bibr" rid="ref-9">9</xref>,
<xref ref-type="bibr" rid="ref-35">35</xref>–
<xref ref-type="bibr" rid="ref-37">37</xref></sup>.</p>
<table-wrap id="T1" orientation="portrait" position="anchor">
<label>Table 1. </label>
<caption>
<title>Heart Rhythm Society/European Society of Cardiology recommendations for the diagnosis and treatment of genetic arrhythmia syndrome and inherited cardiomyopathies.</title>
</caption>
<table content-type="article-table" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Genetic
<break></break>arrhythmia
<break></break>syndrome</th>
<th align="left" colspan="1" rowspan="1">Associated gene and ion channel
<break></break>affected</th>
<th align="left" colspan="1" rowspan="1">Recommendations for diagnosis</th>
<th align="left" colspan="1" rowspan="1">Recommendations for treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1" valign="top">LQTS</td>
<td colspan="1" rowspan="1" valign="top">   •   Associated with mutations in at
<break></break>least 15 genes
<break></break>   •   Three main genes:
<italic>KCNQ1</italic>
<break></break>(LQTS1),
<italic>KNCH2</italic> (LQTS2), and
<break></break>
<italic>SCN5A</italic> (LQTS3) (75% of cases)
<break></break>   •   
<italic>IKr</italic> (LQTS1),
<italic>IKs</italic> (LQTS2),
<italic>INa</italic>
<break></break>(LQTS3),
<italic>IK1</italic> (LQTS7), and
<italic>ICa-L</italic>
<break></break>(LQTS8)
<break></break>   •   AD LQTS with QT prolongation
<break></break>alone (Romano-Ward syndrome)
<break></break>LQTS 1–6
<break></break>   •   AD LQTS7 (Anderson-Tawil
<break></break>syndrome): facial dysmorphism
<break></break>and hyper/hypokalemic periodic
<break></break>paralysis
<break></break>   •   AD LQTS8 (Timothy
<break></break>syndrome) prolonged QT,
<break></break>facial dysmorphism, cardiac
<break></break>malformations, and autism
<break></break>   •   Autosomal recessive LQTS
<break></break>(Jervell and Lange-Nielson
<break></break>syndrome) extremely prolonged
<break></break>QT interval with congenital
<break></break>deafness</td>
<td colspan="1" rowspan="1" valign="top">   •   QTc ≥ 480 ms in repeated 12-
<break></break>lead ECGs or LQTS risk score &gt;3
<break></break>(class I)
<break></break>   •   Confirmed pathogenic LQTS
<break></break>mutations (class I)
<break></break>   •   QTc ≥ 460 ms with unexplained
<break></break>syncopal episode in the absence of secondary
<break></break>causes of QT
<break></break>prolongation</td>
<td colspan="1" rowspan="1" valign="top">   •   Avoid QT prolonging agents, correct
<break></break>electrolytes, and avoid genotype-
<break></break>specific triggers (for example,
<break></break>strenuous exercise for LQTS1 and
<break></break>loud noise for LQTS2)
<break></break>   •   BBs are recommended for patients
<break></break>with clinical diagnosis (class I) and
<break></break>carriers of causative mutation and
<break></break>normal QTc (class IIa)
<break></break>   •   ICD should be implanted in patients
<break></break>with prior SCA (class I), syncope
<break></break>and/or VT while on adequately
<break></break>dosed BBs (class IIa) or considered
<break></break>in addition to BBs in asymptomatic
<break></break>carriers of
<italic>KCNH2</italic> or
<italic>SCN5A</italic>
<break></break>mutations and a QTc &gt; 500 ms
<break></break>   •   LCSD can be attempted in patients
<break></break>with ineffective or poorly tolerated
<break></break>BB therapy, contraindication to ICD,
<break></break>or incessant VT, multiple ICD shocks
<break></break>(class IIa)
<break></break>   •   Sodium channel blockers
<break></break>(Mexiletine, Flecainide, Ranolazine)
<break></break>may be used as adjunctive therapy
<break></break>in LQTS3 with QTc &gt;500 ms
<break></break>   •   Invasive EPS and PVS is not
<break></break>recommended for risk stratification (class III)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">SQTS</td>
<td colspan="1" rowspan="1" valign="top">   •   
<italic>KCNH2</italic> (SQT1),
<italic>KCNQ1</italic> (SQT2),
<break></break>and
<italic>KCNJ2</italic> (SQT3)
<break></break>   •   
<italic>IKr</italic> (SQT1),
<italic>IKs</italic> (SQT2), and
<italic>IK1</italic>
<break></break>(SQT3)</td>
<td colspan="1" rowspan="1" valign="top">   •   QTc ≤ 340 ms on ECG (class I)
<break></break>   •   QTc ≤ 360 ms and confirmed
<break></break>pathogenic mutation, family
<break></break>history of SQTS, family history
<break></break>of SCD &lt;40 years, survival from
<break></break>VT/VF in the absence of heart
<break></break>disease (class IIa)</td>
<td colspan="1" rowspan="1" valign="top">   •   ICD implant is recommended in
<break></break>patients with spontaneous sustained
<break></break>VT or SCA (class I)
<break></break>   •   Quinidine or sotalol are
<break></break>recommended in patients who
<break></break>refuse or have a contraindication to
<break></break>ICD or in asymptomatic patients with
<break></break>SQTS and a family history of SCD
<break></break>(class IIb)
<break></break>   •   Invasive EPS and PVS are not
<break></break>recommended for risk stratification
<break></break>(class III).</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">BrS</td>
<td colspan="1" rowspan="1" valign="top">   •   Inherited AD
<break></break>   •   12 genetic mutations identified
<break></break>   •   
<italic>SCN5A</italic> and
<italic>CACN1Ac</italic> (account for
<break></break>more than 5% of positively
<break></break>genotyped patients)
<break></break>   •   Genetic screening does not affect
<break></break>treatment or prognosis.</td>
<td colspan="1" rowspan="1" valign="top">   •   ST-segment elevation with type
<break></break>1 morphology ≥2 mm elevation
<break></break>in one or more right precordial
<break></break>leads V1 and/or V2 positioned
<break></break>in the second, third, or fourth
<break></break>intercostal space, occurring either
<break></break>spontaneously or after provocative
<break></break>drug test with intravenous
<break></break>administration of sodium channel
<break></break>blockers such as ajmaline,
<break></break>flecainide, and procainamide
<break></break>(class I)</td>
<td colspan="1" rowspan="1" valign="top">   •   Lifestyle changes: Patients should
<break></break>avoid drugs that may induce
<break></break>ST elevation, excessive alcohol
<break></break>consumption, and seek prompt
<break></break>treatment of fever (class I)
<break></break>   •   ICD implantation is recommended in
<break></break>survivors of SCA and/or spontaneous
<break></break>sustained VT or both (class I) or in
<break></break>patients with spontaneous Brugada
<break></break>pattern and history of syncope
<break></break>(class IIa) or patients with diagnosis
<break></break>of BrS who develop VF during PVS with
<break></break>two or three extra stimuli at two sites
<break></break>(class IIb)
<break></break>   •   Quinidine or isoproterenol to be
<break></break>considered in electrical storm (class
<break></break>IIa). Quinidine should be considered
<break></break>in patients with BrS who refuse
<break></break>or have a contraindication to ICD
<break></break>implantation (class IIa)
<break></break>   •   Catheter ablation may be considered
<break></break>in patients with repeated ICD shocks
<break></break>and electrical storm (class IIb).</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">ERS</td>
<td colspan="1" rowspan="1" valign="top">   •   Polygenic
<break></break>   •   Role of genetic screening is not
<break></break>clear
<break></break>   •   
<italic>IK-ATP</italic> (ERS1, 5),
<italic>ICa</italic> (ERS2-4),
<break></break>and
<italic>INa</italic> (ERS6)
<break></break>   •   No clear familial transmission</td>
<td colspan="1" rowspan="1" valign="top">   •   Asymptomatic early repolarization
<break></break>pattern is common in general
<break></break>population.
<break></break>   •   ERS diagnosed only in patients
<break></break>with a pattern and documented
<break></break>idiopathic VF or polymorphic VT</td>
<td colspan="1" rowspan="1" valign="top">   •   Insufficient evidence to make
<break></break>definitive recommendations</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">CPVT</td>
<td colspan="1" rowspan="1" valign="top">   •   Dominant variant: ryanodine
<break></break>receptor gene (
<italic>RyR2</italic>)
<break></break>   •   Rare recessive variant: cardiac
<break></break>calsequestrin gene (
<italic>CASQ2</italic>)
<break></break>   •   Other genes:
<italic>KCNJ2, Ank2,</italic>
<break></break>
<italic>TRDN</italic>, and
<italic>CALM1</italic>
</td>
<td colspan="1" rowspan="1" valign="top">   •   Induction of bidirectional or
<break></break>polymorphic VT in the presence of
<break></break>structurally normal heart and ECG
<break></break>(class I)
<break></break>   •   Diagnosed carriers of a
<break></break>pathogenic mutation on genetic
<break></break>screening (
<italic>RyR2</italic> or
<italic>CASQ2</italic>)</td>
<td colspan="1" rowspan="1" valign="top">   •   Avoidance of competitive sports,
<break></break>stress environments, and strenuous
<break></break>exercise (class I)
<break></break>   •   BBs recommended for all patients
<break></break>(class I), genetically positive family
<break></break>members of proband without
<break></break>exercise induced VT (class IIa)
<break></break>   •   Flecainide should be considered
<break></break>in addition to BBs in patients with
<break></break>recurrent syncope or VT or with
<break></break>contraindication to ICD (class IIa)
<break></break>or in patients with ICD to reduce
<break></break>shocks (class IIa)
<break></break>•   ICD and BBs and/or flecainide
<break></break>in patients with SCA, recurrent
<break></break>syncope, or polymorphic VT despite
<break></break>optimal therapy (class I)
<break></break>•   LCSD can be performed in CPVT
<break></break>patients with recurrent syncope,
<break></break>arrhythmia, recurrent ICD shocks
<break></break>while on maximal therapy or who are
<break></break>intolerant to medical therapy (class IIb)
<break></break>   •   Invasive EPS with PVS is not
<break></break>recommended for risk stratification
<break></break>(class III).</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">HCM</td>
<td colspan="1" rowspan="1" valign="top">   •   AD
<break></break>   •   10 genes encoding from proteins
<break></break>in cardiac sarcomere
<break></break>   •   Beta-myosin, troponin T and I,
<break></break>alpha-tropomyosin, myosin light
<break></break>chains, titin, alpha actin, alpha
<break></break>myosin heavy chain, and muscle
<break></break>LIM protein (MLP)
<break></break>   •   Non-sarcomeric protein mutations
<break></break>(storage disease) clinically similar
<break></break>
<italic>PRKAG2, LAMP2</italic>
<break></break>   •   Commercially available genetic
<break></break>testing</td>
<td colspan="1" rowspan="1" valign="top">   •   Left ventricular hypertrophy
<break></break>max wall thickness ≥15 mm,
<break></break>asymmetric (&gt;1.3:1), concomitant
<break></break>obstructive pathology and
<break></break>mitral regurgitation, diastolic
<break></break>dysfunction, abnormal papillary
<break></break>muscles on transthoracic
<break></break>echocardiography or cardiac
<break></break>magnetic resonance imaging
<break></break>(class I)
<break></break>   •   Genetic testing is recommended
<break></break>in index patient and family
<break></break>members (class I)</td>
<td colspan="1" rowspan="1" valign="top">   •   Avoidance of competitive sports,
<break></break>stress environments, and strenuous
<break></break>exercise (class I)
<break></break>   •   ICD in survivors of SCA or sustained
<break></break>VT/VF causing syncope (class I)
<break></break>   •   Risk stratification with HCM SCD
<break></break>risk calculator (class I)
<break></break>   •   BBs or calcium channel blockers
<break></break>(class I) or disopyramide (class IIa)
<break></break>to treat obstructive symptoms.
<break></break>Guideline-directed medical therapy
<break></break>for congestive heart failure (class IIa)
<break></break>   •   Invasive EPS with PVS is not
<break></break>recommended for risk stratification
<break></break>of SCD (class III)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AD, autosomal dominant; BB, beta blocker; BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ECG, electrocardiogram; EPS, electrophysiologic study; ERS, early repolarization syndrome; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LQTS, long QT syndrome; LCSD left cervical sympathetic denervation; PVS, programmed ventricular stimulation; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SQTS, short QT syndrome; VF, ventricular fibrillation; VT, ventricular tachycardia.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>An important breakthrough in treating genetic arrhythmia syndromes has been the identification of a potential arrhythmic substrate located in the epicardial right ventricular outflow tract (RVOT) that may trigger VT/VF in some patients with Brugada syndrome. Epicardial 3D EAM has shown abnormal low voltage and fractionated late potentials clustered exclusively in the anterior RVOT epicardium. Ablation at these sites rendered VT/VF non-inducible in 78% and normalization of the Brugada ECG pattern (coved ST-elevations in V1 and V2) in 89%. A multicenter randomized study—Ablation in Brugada Syndrome for the Prevention of VF episodes (BRAVE Study)—is being planned and will assess long-term outcomes of catheter ablation in patients with Brugada syndrome
<sup><xref ref-type="bibr" rid="ref-38">38</xref>,
<xref ref-type="bibr" rid="ref-39">39</xref></sup>.</p>
</sec>
<sec>
<title>Medical management of ventricular tachycardia in structural heart disease: Will there be a realm beyond amiodarone therapy?</title>
<p>Pharmacologic therapy for preventing VAs has yielded disappointing results in recent years. Therapy has been limited because of variable efficacy, pro-arrhythmic effects, patient compliance, and adverse effects from long-term therapy. As adjuvant suppressive therapy in patients with ICDs, amiodarone and sotalol have been shown to reduce the rate of recurrent VT (71% and 15–44%, respectively) when compared with beta-blockers or placebo
<sup><xref ref-type="bibr" rid="ref-40">40</xref></sup>. Current guidelines recommend pharmacologic therapy (amiodarone or sotalol) with or without adjunctive catheter ablation to prevent VT/VF recurrence and reducing ICD shocks
<sup><xref ref-type="bibr" rid="ref-8">8</xref>,
<xref ref-type="bibr" rid="ref-16">16</xref></sup>.</p>
<p>Intravenous amiodarone and sodium channel blockers (lidocaine and procainamide) remain the preferred drug regimen in the acute setting; however, more recently, intravenous sotalol has been shown to terminate sustained VT acutely with a higher efficacy versus lidocaine
<sup><xref ref-type="bibr" rid="ref-41">41</xref></sup>. Neither amiodarone nor lidocaine, however, has been shown to improve survival or neurologic outcomes in patients with pulseless VT/VF and out-of-hospital cardiac arrest
<sup><xref ref-type="bibr" rid="ref-42">42</xref></sup>. In the first prospective randomized study comparing intravenous procainamide and amiodarone in the acute treatment of hemodynamically tolerated wide complex tachycardia (VAs), procainamide was shown to be more efficacious in tachycardia termination (67% versus 38%) and was associated with fewer major cardiovascular events (9% versus 41%). The effect was consistently observed even in those with structural heart disease as well as when adjusted for age and sex. Although this study had a limited number of patients and was not blinded, it still points to the efficacy and safety of intravenous procainamide in the acute treatment of VT
<sup><xref ref-type="bibr" rid="ref-43">43</xref></sup>.</p>
<p>Investigators of the VANISH trial showed an improved composite primary outcome of death, VT storm, or appropriate ICD shocks among patients undergoing catheter ablation versus escalation of anti-arrhythmic drug therapy (amiodarone or mexiletine or both) but with no significant difference between groups in terms of mortality
<sup><xref ref-type="bibr" rid="ref-44">44</xref></sup>. In a recent meta-analysis comparing the effectiveness of anti-arrhythmic drugs versus catheter ablation for preventing recurrent VT in patients with ICDs, there was no significant difference between the two treatment modalities (odds ratio (OR) 0.58, 95% confidence interval (CI) 0.26–1.2,
<italic>P</italic> = 0.17) in terms of risk reduction of VT as well as all-cause mortality (OR 0.58, 95% CI 0.24–1.24,
<italic>P</italic> = 0.23)
<sup><xref ref-type="bibr" rid="ref-10">10</xref></sup>. To avoid potential long-term adverse effects and reduce mortality, amiodarone may be safely reduced or discontinued after successful VT ablation without an increase in VT recurrence
<sup><xref ref-type="bibr" rid="ref-45">45</xref></sup>.</p>
<p>Nifekalant, a pure potassium channel blocker that has been approved for use in Japan for VT since 1999, has not been shown to be superior to amiodarone in treating out-of-hospital cardiac arrest or shock-resistant sustained VT/VF
<sup><xref ref-type="bibr" rid="ref-46">46</xref>,
<xref ref-type="bibr" rid="ref-47">47</xref></sup>. Azimilide, another class III agent (not approved in the US), has been shown to reduce VAs and appropriate ICD shocks in patients with cardiomyopathies, according to data from the SHIELD trial
<sup><xref ref-type="bibr" rid="ref-48">48</xref></sup>.</p>
<p>Development of efficacious anti-arrhythmic drugs for VAs with a limited adverse-effect profile continues to be a challenge.</p>
</sec>
<sec>
<title>What lies in the future for implantable device therapy</title>
<p>Next to guideline-directed medical therapy, ICDs can reduce the risk of sudden cardiac death according to several randomized controlled trials for secondary prevention in both ischemic cardiomyopathy and NICM
<sup><xref ref-type="bibr" rid="ref-11">11</xref></sup>. For primary prevention of sudden cardiac death, particularly in NICM, the benefit from ICD has been modest primarily because of a lower rate of spontaneous VT/VF. The DANISH investigators
<sup><xref ref-type="bibr" rid="ref-49">49</xref></sup> showed no significant overall mortality benefit from primary prevention ICD implantation in patients with NICM and symptomatic heart failure. Importantly, this observation seems to be age-dependent as patients younger than 59 years derive significant benefit from the ICD.</p>
<p>Intravascular lead-related complications and inappropriate shocks are of particular significance in young patients with channelopathies and syndromes who are also at high risk for fatal VAs. ICD arrhythmia detection and programming algorithms have been refined over time to include higher minimum cutoff rates, extended detection time for VT, anti-tachycardia pacing, and morphology discriminators to minimize the risk of inappropriate shocks
<sup><xref ref-type="bibr" rid="ref-11">11</xref>,
<xref ref-type="bibr" rid="ref-50">50</xref></sup>.</p>
<p>The development of an entirely subcutaneous ICD (S-ICD) system with efficacy similar to that of conventional ICD in terminating VT/VF has been a major advance in device technology
<sup><xref ref-type="bibr" rid="ref-51">51</xref>,
<xref ref-type="bibr" rid="ref-52">52</xref></sup>. Although randomized comparative data are not yet available, pooled data from the EFFORTLESS and IDE trials have shown the S-ICD to be a safe and effective alternative to conventional transvenous ICDs—especially in younger patients with HCM, genetic channelopathies, and adult complex congenital heart disease—as long as there is no need for pacing
<sup><xref ref-type="bibr" rid="ref-52">52</xref>–
<xref ref-type="bibr" rid="ref-55">55</xref></sup>. The rate of inappropriate shocks due to oversensing has been mitigated with the introduction of dual zone programming and algorithms to accommodate R- and T-wave amplitude variations
<sup><xref ref-type="bibr" rid="ref-56">56</xref></sup>.</p>
<p>Two additional trials—PRAETORIAN and UNTOUCHED—will provide definitive data regarding a direct comparison of the S-ICD with a transvenous ICD system in terms of efficacy, appropriate and inappropriate shocks, and ICD-related complications
<sup><xref ref-type="bibr" rid="ref-57">57</xref>,
<xref ref-type="bibr" rid="ref-58">58</xref></sup>. An investigational percutaneous implantable intravascular defibrillator has also been developed that, compared with conventional ICD, has potentially lower complications and similar defibrillation thresholds
<sup><xref ref-type="bibr" rid="ref-59">59</xref></sup>.</p>
</sec>
<sec>
<title>Invasive mapping and catheter ablation of ventricular tachycardia: Have we built the right tools to decode the substrate?</title>
<p>Catheter ablation guided by 3D EAM has emerged as an effective therapeutic option in patients with recurrent and sustained monomorphic VT, arrhythmia-induced cardiomyopathy, recurrent ICD shocks, intolerance to anti-arrhythmic medications, or a combination of these
<sup><xref ref-type="bibr" rid="ref-16">16</xref></sup>. Catheter ablation of VT has a reported complication rate ranging from 5 to 7% according to different studies and has low periprocedural mortality and VT termination in up to 70% of cases
<sup><xref ref-type="bibr" rid="ref-16">16</xref>,
<xref ref-type="bibr" rid="ref-60">60</xref>,
<xref ref-type="bibr" rid="ref-61">61</xref></sup>. The recurrence rate, however, remains high; 26 to 50% of patients experience recurrent VT during long-term follow-up
<sup><xref ref-type="bibr" rid="ref-17">17</xref>,
<xref ref-type="bibr" rid="ref-62">62</xref></sup>.</p>
<p>The success rate of catheter ablation for scar-mediated VT is higher in ischemic cardiomyopathy
<sup><xref ref-type="bibr" rid="ref-63">63</xref></sup>. Substrate-guided VT ablation remains the preferred approach particularly when the arrhythmia is poorly tolerated. The VISTA trial showed an extensive substrate-based approach to be superior when compared with targeting clinical VT (15.5% VT recurrence in substrate-guided versus 48.3% in the clinical VT target group) in patients with ischemic cardiomyopathy
<sup><xref ref-type="bibr" rid="ref-64">64</xref></sup>. The limitation in achieving higher success in NICM may be related to the more heterogeneous distribution of disease as well as transmurality and epicardial extension of scar
<sup><xref ref-type="bibr" rid="ref-62">62</xref></sup>.</p>
<p>Kumar
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-65">65</xref></sup> reported better survival and low VT recurrence in patients without structural heart disease undergoing catheter ablation of VT compared with those with ischemic and non-ischemic cardiomyopathy. During long-term follow-up, the highest VA recurrence was seen in NICM (about 75% of those with NICM had at least one VA recurrence) but patients with ischemic cardiomyopathy had higher overall mortality.</p>
<p>Although we have limited data from randomized controlled trials and no proven mortality benefit yet for VT ablation in structural heart disease, recent studies do suggest that ablation results in improved quality of life, freedom from ICD shocks, and improved transplant-free survival. Tung
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-66">66</xref></sup> reported 1-year freedom from VT recurrence in up to 70% of patients with structural heart disease who underwent VT ablation (including 72% of patients with ischemic cardiomyopathy and 68% with NICM). Lack of recurrent VT translated as an improved transplant-free survival in this study
<sup><xref ref-type="bibr" rid="ref-66">66</xref></sup>. Data from the THERMOCOOL VT trial looking at the long-term success of open irrigated radiofrequency (RF) catheter ablation of monomorphic VT associated with coronary artery disease showed reduced ICD shocks and VT episodes with improved quality of life at 6 months. At 3-year follow-up, non-recurrence resulted in decreased amiodarone use and hospitalizations
<sup><xref ref-type="bibr" rid="ref-67">67</xref></sup>.</p>
<p>Other investigational and clinically tested techniques that could potentially improve substrate characterization, procedural outcomes and minimize complications include use of irrigated and contact force ablation catheters, incorporation of pre-procedural and intra-procedural imaging, ablation of deep myocardial substrate with bipolar RF ablation, transcoronary alcohol injection, coronary coil embolization, epicardial ablation, surgical cryoablation, and remote magnetic navigation, and stereotactic ablative radiotherapy (
<xref ref-type="table" rid="T2">Table 2</xref>)
<sup><xref ref-type="bibr" rid="ref-68">68</xref>–
<xref ref-type="bibr" rid="ref-78">78</xref></sup>. However, concrete data on the efficacy of these techniques is lacking and further studies are needed.</p>
<table-wrap id="T2" orientation="portrait" position="anchor">
<label>Table 2. </label>
<caption>
<title>Investigational modalities for ventricular tachycardia ablation and suggested clinical applications.</title>
</caption>
<table content-type="article-table" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Innovative modality</th>
<th align="left" colspan="1" rowspan="1">Investigators and initial reports</th>
<th align="left" colspan="1" rowspan="1">Salient features and possible benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1" valign="top">MRI-guided stereotactic ablative radiotherapy
<break></break>   •   For patients with VT who have failed
<break></break>standard therapy
<break></break>   •   Uses anatomic scar imaging: MRI or
<break></break>SPECT or both with superimposed voltage
<break></break>map to accurately delineate scar</td>
<td colspan="1" rowspan="1" valign="top">Cuculich
<italic>et al</italic>. - ENCORE-VT
<break></break>phase I/II study
<sup><xref ref-type="bibr" rid="ref-83">83</xref></sup>
<break></break>Clinical trial: NCT02919618
<break></break>Loo
<italic>et al</italic>. Stereotactic Ablative
<break></break>Radiotherapy (STAR)
<sup><xref ref-type="bibr" rid="ref-84">84</xref></sup>
<break></break>Maguire
<italic>et al</italic>. - CyberHeart’s
<break></break>Cardiac Arrhythmia Ablation
<sup><xref ref-type="bibr" rid="ref-85">85</xref></sup>
<break></break>Clinical trial: NCT02661048 </td>
<td colspan="1" rowspan="1" valign="top">   •   A rapid and totally non-invasive
<break></break>technique
<break></break>   •   Pre-clinical data suggest significant
<break></break>reduction in VT burden (&gt;50%) and
<break></break>reduction in implantable cardioverter
<break></break>defibrillator therapy (&gt;85%).
<break></break>   •   Clinical trials to determine the acute and
<break></break>long-term safety and efficacy initiated
<break></break>   •   Gap-free ablation can be performed
<break></break>in short duration for medically frail
<break></break>population</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Infusion needle catheter ablation
<break></break>   •   Infusion needle catheter ablation is being
<break></break>studied for effectiveness in patients
<break></break>who have failed standard RF ablation,
<break></break>especially with deep mid-myocardial
<break></break>substrate for VT
<break></break>   •   Needle design allows for myocardial
<break></break>penetration, infusion of heated saline and
<break></break>RF energy delivery
<break></break>   •   Pre- and peri-procedural imaging helps
<break></break>guide the procedure (e.g; intracardiac
<break></break>echocardiography)</td>
<td colspan="1" rowspan="1" valign="top">Sapp
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-77">77</xref></sup>
<break></break>Stevenson
<italic>et al</italic>. Intramural Needle
<break></break>Ablation for Recurrent Ventricle
<break></break>Tachycardia
<sup><xref ref-type="bibr" rid="ref-86">86</xref></sup>
<break></break>Clinical trial: NCT01791543</td>
<td colspan="1" rowspan="1" valign="top">   •   A bipolar or quadripolar catheter
<break></break>equipped with an extensible needle that
<break></break>can project up to 12 mm beyond tip is
<break></break>used
<break></break>   •   Heated saline can be infused through tip
<break></break>and side pores
<break></break>   •   Flow rate of saline determines lesion size
<break></break>   •   Large lesions can be created, does not
<break></break>require scar/lesion maturity</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Facilitated RF ablation using magnetically
<break></break>directed nanoparticles
<break></break>   •   Iron, carbon, or titanium nanoparticles are
<break></break>delivered within heat-sensitive liposomes
<break></break>   •   Iron nanoparticles used in imaging
<break></break>considered safe
<break></break>   •   Study
<italic>in vivo</italic> porcine models</td>
<td colspan="1" rowspan="1" valign="top">Nguyen
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-87">87</xref></sup>
</td>
<td colspan="1" rowspan="1" valign="top">   •   Nanoparticles have been shown to alter
<break></break>tissue sensitivity to RF energy with a
<break></break>potential to create deeper lesions
<break></break>   •   Better tissue heating avoids “steam
<break></break>pops”</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">MRI-based signal intensity mapping for epicardial
<break></break>substrate
<break></break>   •   The technique helps to identify epicardial
<break></break>substrate for monomorphic VT with
<break></break>contrast enhanced MRI
<break></break>   •   Images can be correlated with standard
<break></break>electroanatomical mapping
<break></break>   •   Clinical data based on
<italic>in vivo</italic> porcine
<break></break>models available</td>
<td colspan="1" rowspan="1" valign="top">Arenal
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-33">33</xref></sup>
</td>
<td colspan="1" rowspan="1" valign="top">   •   Epicardial VT substrate can be identified
<break></break>by contrast-enhanced MRI-based signal
<break></break>intensity mapping
<break></break>   •   Patchy scar pattern may be associated
<break></break>with VT inducibility
<break></break>   •   Potential non-invasive imaging modality
<break></break>to determine risk of inducible epicardial
<break></break>VT prior to planned procedure</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">MIBG imaging to guide VT ablation
<break></break>   •   MIBG has characteristics similar to
<break></break>those of norepinephrine; it is taken up at
<break></break>presynaptic neurons
<break></break>   •   3D models with MIBG are created to
<break></break>guide VT ablation
<break></break>   •   A 15-patient feasibility study
<break></break>   •   ADMIRE trial identified areas of cardiac
<break></break>denervation and correlations with death,
<break></break>heart failure, and VT/ventricular fibrillation
<break></break>   •   MIBG (scan) US Food and Drug
<break></break>Administration-approved 2013</td>
<td colspan="1" rowspan="1" valign="top">Klein
<italic>et al</italic>. - 3D MIBG Innervation
<break></break>Maps to assess substrate and
<break></break>successful ablation sites for VT
<sup><xref ref-type="bibr" rid="ref-88">88</xref></sup>
<break></break>Jacobson
<italic>et al</italic>. ADMIRE-HF
<sup><xref ref-type="bibr" rid="ref-89">89</xref></sup>
</td>
<td colspan="1" rowspan="1" valign="top">   •   MIBG innervation defects are larger than
<break></break>scars created with bipolar voltage maps.
<break></break>   •   In the pilot study 36% successful
<break></break>ablative sites were located in areas
<break></break>of abnormal innervation and normal
<break></break>voltage
<break></break>   •   Voltage maps do not necessarily
<break></break>correlate with innervation maps.
<break></break>   •   Innervation maps may help target
<break></break>additional sites of VT ablation not
<break></break>identified by EAM</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Non-invasive high-resolution mapping and ECGI
<break></break>   •   This technique offers single-beat
<break></break>panoramic mapping
<break></break>   •   Both endocardial and epicardial mapping
<break></break>can be performed</td>
<td colspan="1" rowspan="1" valign="top">Reports from 1998 to 2015; Rudy
<break></break>
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-90">90</xref>,
<xref ref-type="bibr" rid="ref-91">91</xref></sup>
<break></break>Zhang
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-92">92</xref></sup>
</td>
<td colspan="1" rowspan="1" valign="top">   •   Non-invasive modality to provide
<break></break>endocardial and epicardial substrate
<break></break>information
<break></break>   •   Information can be used to risk-stratify
<break></break>patients and identify those at highest risk
<break></break>of ventricular arrhythmia.
<break></break>   •   ECGI has been shown to have a high
<break></break>correlation with MRI and SPECT derived
<break></break>scar
<break></break>   •   Anti-arrhythmic drug exposure could
<break></break>potentially affect amplitude and
<break></break>fractionation.</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Cardiac ripple mapping for slow conducting
<break></break>channels
<break></break>   •   A novel method to incorporate voltage and
<break></break>activation data for EAM mapping
<break></break>   •   High-density bipolar electrograms
<break></break>collected</td>
<td colspan="1" rowspan="1" valign="top">Luther
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-93">93</xref></sup>
<break></break>Jamil-Copley
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-94">94</xref></sup>
</td>
<td colspan="1" rowspan="1" valign="top">   •   Allows for simultaneous visualization of
<break></break>voltage and activation data incorporated
<break></break>on 3D EAM
<break></break>   •   Enables identification of slow
<break></break>conduction channels within scar zones
<break></break>in myocardium that may be potential
<break></break>targets of VT ablation
<break></break>   •   Target-specific approach can improve
<break></break>efficacy of ablation.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>3D, three-dimensional; EAM, electroanatomic map; ECGI, electrocardiographic imaging; MIBG,
<sup>123</sup>I-meta-iodobenzylguanidine; MRI, magnetic resonance imaging; RF, radiofrequency; SPECT, single-photon emission computed tomography; VT, ventricular tachycardia.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>However, concrete data for their efficacy are lacking and more studies are needed. Epicardial substrate ablation has been identified as a potentially successful ablation strategy to eliminate VAs in select patients with ARVD and NICM and more recently in patients with Brugada syndrome
<sup><xref ref-type="bibr" rid="ref-38">38</xref>,
<xref ref-type="bibr" rid="ref-39">39</xref>,
<xref ref-type="bibr" rid="ref-79">79</xref></sup>. In patients with incessant VT who have failed conventional and ablative therapy, left or bilateral cervical sympathectomy has been shown in observational studies to reduce VT recurrence, but larger studies are needed to establish the safety and efficacy of this procedure
<sup><xref ref-type="bibr" rid="ref-80">80</xref>–
<xref ref-type="bibr" rid="ref-82">82</xref></sup>.</p>
</sec>
<sec sec-type="conclusions">
<title>Conclusions</title>
<p>VAs encompass a broad range of clinical conditions ranging from benign to life-threatening. Sustained VAs are a major cause of morbidity and mortality in patients with structural heart disease. In addition to refinement and evolution of well-established therapies such as anti-arrhythmic drugs and ICDs, several major advances in the mechanistic, genetic, diagnostic, and therapeutic realms have furthered our understanding of the pathophysiology of ventricular tachyarrhythmias and helped fashion safer and more effective therapies particularly for drug-refractory VAs. Several gaps in our knowledge remain and require further research. Ultimately, successful short- and long-term management of VAs will likely integrate biological, pharmacologic, device-based, and ablative therapies.</p>
</sec>
<sec>
<title>Abbreviations</title>
<p>3D, three-dimensional; ARVD, arrhythmogenic right ventricular dysplasia; CI, confidence interval; CMR, cardiac magnetic resonance imaging; CT, computed tomography; EAM, electroanatomic mapping; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; MRI, magnetic resonance imaging; NICM, non-ischemic cardiomyopathy; OR, odds ratio; RF, radiofrequency; RVOT, right ventricular outflow tract; S-ICD, subcutaneous ICD; VA, ventricular arrhythmia; VF, ventricular fibrillation; VT, ventricular tachycardia.</p>
</sec>
</body>
<back>
<ref-list>
<ref id="ref-1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Roger</surname><given-names>VL</given-names></name><etal></etal></person-group>:
<article-title>Heart disease and stroke statistics--2014 update: a report from the American Heart Association.</article-title>
<source/><italic>Circulation.</italic>
<year>2014</year>;<volume>129</volume>(<issue>3</issue>):<fpage>e28</fpage>–<lpage>e292</lpage>.
<pub-id pub-id-type="doi">10.1161/01.cir.0000441139.02102.80</pub-id>
<!--<pub-id pub-id-type="pmcid">5408159</pub-id>-->
<pub-id pub-id-type="pmid">24352519</pub-id></mixed-citation>
</ref>
<ref id="ref-2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weisfeldt</surname><given-names>ML</given-names></name><name><surname>Everson-Stewart</surname><given-names>S</given-names></name><name><surname>Sitlani</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Ventricular tachyarrhythmias after cardiac arrest in public versus at home.</article-title>
<source/><italic>N Engl J Med.</italic>
<year>2011</year>;<volume>364</volume>(<issue>4</issue>):<fpage>313</fpage>–<lpage>21</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa1010663</pub-id>
<!--<pub-id pub-id-type="pmcid">3062845</pub-id>-->
<pub-id pub-id-type="pmid">21268723</pub-id></mixed-citation>
</ref>
<ref id="ref-3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lo</surname><given-names>R</given-names></name><name><surname>Chia</surname><given-names>KK</given-names></name><name><surname>Hsia</surname><given-names>HH</given-names></name></person-group>:
<article-title>Ventricular Tachycardia in Ischemic Heart Disease.</article-title>
<source/><italic>Card Electrophysiol Clin.</italic>
<year>2017</year>;<volume>9</volume>(<issue>1</issue>):<fpage>25</fpage>–<lpage>46</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ccep.2016.10.013</pub-id>
<pub-id pub-id-type="pmid">28167084</pub-id></mixed-citation>
</ref>
<ref id="ref-4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benito</surname><given-names>B</given-names></name><name><surname>Guasch</surname><given-names>E</given-names></name><name><surname>Rivard</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>Clinical and mechanistic issues in early repolarization of normal variants and lethal arrhythmia syndromes.</article-title>
<source/><italic>J Am Coll Cardiol.</italic>
<year>2010</year>;<volume>56</volume>(<issue>15</issue>):<fpage>1177</fpage>–<lpage>86</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jacc.2010.05.037</pub-id>
<pub-id pub-id-type="pmid">20883924</pub-id></mixed-citation>
</ref>
<ref id="ref-5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chia</surname><given-names>KK</given-names></name><name><surname>Hsia</surname><given-names>HH</given-names></name></person-group>:
<article-title>Ventricular Tachycardia in Nonischemic Dilated Cardiomyopathy.</article-title>
<source/><italic>Card Electrophysiol Clin.</italic>
<year>2014</year>;<volume>6</volume>(<issue>3</issue>):<fpage>535</fpage>–<lpage>52</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ccep.2014.05.009</pub-id>
</mixed-citation>
</ref>
<ref id="ref-6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>WG</given-names></name></person-group>:
<article-title>Current treatment of ventricular arrhythmias: state of the art.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2013</year>;<volume>10</volume>(<issue>12</issue>):<fpage>1919</fpage>–<lpage>26</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2013.10.019</pub-id>
<pub-id pub-id-type="pmid">24120875</pub-id></mixed-citation>
</ref>
<ref id="ref-7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hohnloser</surname><given-names>SH</given-names></name><name><surname>Israel</surname><given-names>CW</given-names></name></person-group>:
<article-title>Current evidence base for use of the implantable cardioverter-defibrillator.</article-title>
<source/><italic>Circulation.</italic>
<year>2013</year>;<volume>128</volume>(<issue>2</issue>):<fpage>172</fpage>–<lpage>83</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.000547</pub-id>
<pub-id pub-id-type="pmid">23836830</pub-id></mixed-citation>
</ref>
<ref id="ref-8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Priori</surname><given-names>SG</given-names></name><name><surname>Blomström-Lundqvist</surname><given-names>C</given-names></name><name><surname>Mazzanti</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).</article-title>
<source/><italic>Eur Heart J.</italic>
<year>2015</year>;<volume>36</volume>(<issue>41</issue>):<fpage>2793</fpage>–<lpage>867</lpage>.
<pub-id pub-id-type="doi">10.1093/eurheartj/ehv316</pub-id>
<pub-id pub-id-type="pmid">26320108</pub-id></mixed-citation>
</ref>
<ref id="ref-9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Priori</surname><given-names>SG</given-names></name><name><surname>Wilde</surname><given-names>AA</given-names></name><name><surname>Horie</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2013</year>;<volume>10</volume>(<issue>12</issue>):<fpage>1932</fpage>–<lpage>63</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2013.05.014</pub-id>
<pub-id pub-id-type="pmid">24011539</pub-id></mixed-citation>
</ref>
<ref id="ref-10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Santangeli</surname><given-names>P</given-names></name><name><surname>Muser</surname><given-names>D</given-names></name><name><surname>Maeda</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2016</year>;<volume>13</volume>(<issue>7</issue>):<fpage>1552</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2016.03.004</pub-id>
<pub-id pub-id-type="pmid">26961297</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726210190">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Daubert</surname><given-names>JP</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Cannom</surname><given-names>DS</given-names></name><etal></etal></person-group>:
<article-title>Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.</article-title>
<source/><italic>J Am Coll Cardiol.</italic>
<year>2008</year>;<volume>51</volume>(<issue>14</issue>):<fpage>1357</fpage>–<lpage>65</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jacc.2007.09.073</pub-id>
<pub-id pub-id-type="pmid">18387436</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725272447">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>MO</given-names></name><name><surname>Sherfesee</surname><given-names>L</given-names></name><name><surname>DeGroot</surname><given-names>PJ</given-names></name><etal></etal></person-group>:
<article-title>Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2010</year>;<volume>7</volume>(<issue>3</issue>):<fpage>353</fpage>–<lpage>60</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2009.11.027</pub-id>
<pub-id pub-id-type="pmid">20185109</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/720832424">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dev</surname><given-names>S</given-names></name><name><surname>Peterson</surname><given-names>PN</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>Prevalence, correlates, and temporal trends in antiarrhythmic drug use at discharge after implantable cardioverter defibrillator placement (from the National Cardiovascular Data Registry [NCDR]).</article-title>
<source/><italic>Am J Cardiol.</italic>
<year>2014</year>;<volume>113</volume>(<issue>2</issue>):<fpage>314</fpage>–<lpage>20</lpage>.
<pub-id pub-id-type="doi">10.1016/j.amjcard.2013.09.023</pub-id>
<pub-id pub-id-type="pmid">24216126</pub-id></mixed-citation>
</ref>
<ref id="ref-14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Palaniswamy</surname><given-names>C</given-names></name><name><surname>Kolte</surname><given-names>D</given-names></name><name><surname>Harikrishnan</surname><given-names>P</given-names></name><etal></etal></person-group>:
<article-title>Catheter ablation of postinfarction ventricular tachycardia: ten-year trends in utilization, in-hospital complications, and in-hospital mortality in the United States.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2014</year>;<volume>11</volume>(<issue>11</issue>):<fpage>2056</fpage>–<lpage>63</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2014.07.012</pub-id>
<pub-id pub-id-type="pmid">25016150</pub-id></mixed-citation>
</ref>
<ref id="ref-15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuck</surname><given-names>KH</given-names></name><name><surname>Schaumann</surname><given-names>A</given-names></name><name><surname>Eckardt</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial.</article-title>
<source/><italic>Lancet.</italic>
<year>2010</year>;<volume>375</volume>(<issue>9708</issue>):<fpage>31</fpage>–<lpage>40</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(09)61755-4</pub-id>
<pub-id pub-id-type="pmid">20109864</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1643957">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aliot</surname><given-names>EM</given-names></name><name><surname>Stevenson</surname><given-names>WG</given-names></name><name><surname>Almendral-Garrote</surname><given-names>JM</given-names></name><etal></etal></person-group>:
<article-title>EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA).</article-title>
<source/><italic>Europace.</italic>
<year>2009</year>;<volume>11</volume>(<issue>6</issue>):<fpage>771</fpage>–<lpage>817</lpage>.
<pub-id pub-id-type="doi">10.1093/europace/eup098</pub-id>
<pub-id pub-id-type="pmid">19443434</pub-id></mixed-citation>
</ref>
<ref id="ref-17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>JJ</given-names></name><name><surname>Santangeli</surname><given-names>P</given-names></name><name><surname>Callans</surname><given-names>DJ</given-names></name></person-group>:
<article-title>Long-term Outcomes of Ventricular Tachycardia Ablation in Different Types of Structural Heart Disease.</article-title>
<source/><italic>Arrhythm Electrophysiol Rev.</italic>
<year>2015</year>;<volume>4</volume>(<issue>3</issue>):<fpage>177</fpage>–<lpage>83</lpage>.
<pub-id pub-id-type="doi">10.15420/aer.2015.4.3.177</pub-id>
<!--<pub-id pub-id-type="pmcid">4732176</pub-id>-->
<pub-id pub-id-type="pmid">26835122</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726122471">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peck</surname><given-names>KY</given-names></name><name><surname>Lim</surname><given-names>YZ</given-names></name><name><surname>Hopper</surname><given-names>I</given-names></name><etal></etal></person-group>:
<article-title>Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of &gt; 35,000 patients.</article-title>
<source/><italic>Int J Cardiol.</italic>
<year>2014</year>;<volume>173</volume>(<issue>2</issue>):<fpage>197</fpage>–<lpage>203</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ijcard.2014.02.014</pub-id>
<pub-id pub-id-type="pmid">24636548</pub-id></mixed-citation>
</ref>
<ref id="ref-19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeidan-Shwiri</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Lashevsky</surname><given-names>I</given-names></name><etal></etal></person-group>:
<article-title>Magnetic resonance estimates of the extent and heterogeneity of scar tissue in ICD patients with ischemic cardiomyopathy predict ventricular arrhythmia.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2015</year>;<volume>12</volume>(<issue>4</issue>):<fpage>802</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2015.01.007</pub-id>
<pub-id pub-id-type="pmid">25583153</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725312666">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Piers</surname><given-names>SR</given-names></name><name><surname>Tao</surname><given-names>Q</given-names></name><name><surname>van Huls van Taxis</surname><given-names>CF</given-names></name><etal></etal></person-group>:
<article-title>Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy.</article-title>
<source/><italic>Circ Arrhythm Electrophysiol.</italic>
<year>2013</year>;<volume>6</volume>(<issue>5</issue>):<fpage>875</fpage>–<lpage>83</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCEP.113.000537</pub-id>
<pub-id pub-id-type="pmid">24036134</pub-id></mixed-citation>
</ref>
<ref id="ref-21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Piers</surname><given-names>SR</given-names></name><name><surname>Tao</surname><given-names>Q</given-names></name><name><surname>de Riva Silva</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>CMR-based identification of critical isthmus sites of ischemic and nonischemic ventricular tachycardia.</article-title>
<source/><italic>JACC Cardiovasc Imaging.</italic>
<year>2014</year>;<volume>7</volume>(<issue>8</issue>):<fpage>774</fpage>–<lpage>84</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jcmg.2014.03.013</pub-id>
<pub-id pub-id-type="pmid">25051947</pub-id></mixed-citation>
</ref>
<ref id="ref-22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esposito</surname><given-names>A</given-names></name><name><surname>Palmisano</surname><given-names>A</given-names></name><name><surname>Antunes</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Cardiac CT With Delayed Enhancement in the Characterization of Ventricular Tachycardia Structural Substrate: Relationship Between CT-Segmented Scar and Electro-Anatomic Mapping.</article-title>
<source/><italic>JACC Cardiovasc Imaging.</italic>
<year>2016</year>;<volume>9</volume>(<issue>7</issue>):<fpage>822</fpage>–<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jcmg.2015.10.024</pub-id>
<pub-id pub-id-type="pmid">26897692</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726161099">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Acosta</surname><given-names>J</given-names></name><name><surname>Fernández-Armenta</surname><given-names>J</given-names></name><name><surname>Penela</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Infarct transmurality as a criterion for first-line endo-epicardial substrate-guided ventricular tachycardia ablation in ischemic cardiomyopathy.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2016</year>;<volume>13</volume>(<issue>1</issue>):<fpage>85</fpage>–<lpage>95</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2015.07.010</pub-id>
<pub-id pub-id-type="pmid">26165946</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725635884">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dixit</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name></person-group>:
<article-title>Cardiac imaging to define infarct transmurality and guide ventricular tachycardia ablation strategy in patients with ischemic cardiomyopathy.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2016</year>;<volume>13</volume>(<issue>1</issue>):<fpage>96</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2015.08.002</pub-id>
<pub-id pub-id-type="pmid">26253037</pub-id></mixed-citation>
</ref>
<ref id="ref-25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashikaga</surname><given-names>H</given-names></name><name><surname>Arevalo</surname><given-names>H</given-names></name><name><surname>Vadakkumpadan</surname><given-names>F</given-names></name><etal></etal></person-group>:
<article-title>Feasibility of image-based simulation to estimate ablation target in human ventricular arrhythmia.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2013</year>;<volume>10</volume>(<issue>8</issue>):<fpage>1109</fpage>–<lpage>16</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2013.04.015</pub-id>
<!--<pub-id pub-id-type="pmcid">3735782</pub-id>-->
<pub-id pub-id-type="pmid">23608593</pub-id></mixed-citation>
</ref>
<ref id="ref-26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Oikawa</surname><given-names>K</given-names></name><etal></etal></person-group>:
<article-title>Late gadolinium enhancement of cardiac magnetic resonance imaging indicates abnormalities of time-domain T-wave alternans in hypertrophic cardiomyopathy with ventricular tachycardia.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2015</year>;<volume>12</volume>(<issue>8</issue>):<fpage>1747</fpage>–<lpage>55</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2015.04.028</pub-id>
<pub-id pub-id-type="pmid">25916568</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725451610">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chopra</surname><given-names>H</given-names></name><name><surname>Arangalage</surname><given-names>D</given-names></name><name><surname>Bouleti</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Prognostic value of the infarct- and non-infarct like patterns and cardiovascular magnetic resonance parameters on long-term outcome of patients after acute myocarditis.</article-title>
<source/><italic>Int J Cardiol.</italic>
<year>2016</year>;<volume>212</volume>:<fpage>63</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ijcard.2016.03.004</pub-id>
<pub-id pub-id-type="pmid">27035605</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726259146">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Corrado</surname><given-names>D</given-names></name><name><surname>Link</surname><given-names>MS</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name></person-group>:
<article-title>Arrhythmogenic Right Ventricular Cardiomyopathy.</article-title>
<source/><italic>N Engl J Med.</italic>
<year>2017</year>;<volume>376</volume>(<issue>1</issue>):<fpage>61</fpage>–<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMra1509267</pub-id>
<pub-id pub-id-type="pmid">28052233</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727167771">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macias</surname><given-names>C</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Tung</surname><given-names>R</given-names></name><etal></etal></person-group>:
<article-title>Importance Of Delayed Enhanced Cardiac MRI In Idiopathic RVOT-VT: Differentiating Mimics Including Early Stage ARVC And Cardiac Sarcoidosis.</article-title>
<source/><italic>J Atr Fibrillation.</italic>
<year>2014</year>;<volume>7</volume>(<issue>4</issue>):<fpage>1097</fpage>.
<!--<pub-id pub-id-type="pmcid">5135196</pub-id>-->
<pub-id pub-id-type="pmid">27957128</pub-id></mixed-citation>
</ref>
<ref id="ref-30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>CF</given-names></name><etal></etal></person-group>:
<article-title>New insight into scar-related ventricular tachycardia circuits in ischemic cardiomyopathy: Fat deposition after myocardial infarction on computed tomography--A pilot study.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2015</year>;<volume>12</volume>(<issue>7</issue>):<fpage>1508</fpage>–<lpage>18</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2015.03.041</pub-id>
<!--<pub-id pub-id-type="pmcid">4485604</pub-id>-->
<pub-id pub-id-type="pmid">25814415</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725411340">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tung</surname><given-names>R</given-names></name><name><surname>Bauer</surname><given-names>B</given-names></name><name><surname>Schelbert</surname><given-names>H</given-names></name><etal></etal></person-group>:
<article-title>Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2015</year>;<volume>12</volume>(<issue>12</issue>):<fpage>2488</fpage>–<lpage>98</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2015.08.014</pub-id>
<!--<pub-id pub-id-type="pmcid">4656080</pub-id>-->
<pub-id pub-id-type="pmid">26272522</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725721118">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jamil-Copley</surname><given-names>S</given-names></name><name><surname>Bokan</surname><given-names>R</given-names></name><name><surname>Kojodjojo</surname><given-names>P</given-names></name><etal></etal></person-group>:
<article-title>Noninvasive electrocardiographic mapping to guide ablation of outflow tract ventricular arrhythmias.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2014</year>;<volume>11</volume>(<issue>4</issue>):<fpage>587</fpage>–<lpage>94</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2014.01.013</pub-id>
<!--<pub-id pub-id-type="pmcid">4067940</pub-id>-->
<pub-id pub-id-type="pmid">24440381</pub-id></mixed-citation>
</ref>
<ref id="ref-33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arenal</surname><given-names>A</given-names></name><name><surname>Perez-David</surname><given-names>E</given-names></name><name><surname>Avila</surname><given-names>P</given-names></name><etal></etal></person-group>:
<article-title>Noninvasive identification of epicardial ventricular tachycardia substrate by magnetic resonance-based signal intensity mapping.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2014</year>;<volume>11</volume>(<issue>8</issue>):<fpage>1456</fpage>–<lpage>64</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2014.04.022</pub-id>
<pub-id pub-id-type="pmid">24747421</pub-id></mixed-citation>
</ref>
<ref id="ref-34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yokokawa</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>DY</given-names></name><name><surname>Joseph</surname><given-names>KK</given-names></name><etal></etal></person-group>:
<article-title>Computerized analysis of the 12-lead electrocardiogram to identify epicardial ventricular tachycardia exit sites.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2014</year>;<volume>11</volume>(<issue>11</issue>):<fpage>1966</fpage>–<lpage>73</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2014.06.036</pub-id>
<pub-id pub-id-type="pmid">24993461</pub-id></mixed-citation>
</ref>
<ref id="ref-35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandez-Falgueras</surname><given-names>A</given-names></name><name><surname>Sarquella-Brugada</surname><given-names>G</given-names></name><name><surname>Brugada</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Cardiac Channelopathies and Sudden Death: Recent Clinical and Genetic Advances.</article-title>
<source/><italic>Biology (Basel).</italic>
<year>2017</year>;<volume>6</volume>(<issue>1</issue>): pii: E7.
<pub-id pub-id-type="doi">10.3390/biology6010007</pub-id>
<!--<pub-id pub-id-type="pmcid">5372000</pub-id>-->
<pub-id pub-id-type="pmid">28146053</pub-id></mixed-citation>
</ref>
<ref id="ref-36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maron</surname><given-names>BJ</given-names></name><name><surname>Zipes</surname><given-names>DP</given-names></name><name><surname>Kovacs</surname><given-names>RJ</given-names></name></person-group>:
<article-title>Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General Considerations: A Scientific Statement From the American Heart Association and American College of Cardiology.</article-title>
<source/><italic>J Am Coll Cardiol.</italic>
<year>2015</year>;<volume>66</volume>(<issue>21</issue>):<fpage>2343</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jacc.2015.09.032</pub-id>
<pub-id pub-id-type="pmid">26542655</pub-id></mixed-citation>
</ref>
<ref id="ref-37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ostby</surname><given-names>SA</given-names></name><name><surname>Bos</surname><given-names>JM</given-names></name><name><surname>Owen</surname><given-names>HJ</given-names></name><etal></etal></person-group>:
<article-title>Competitive Sports Participation in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia: A Single Center’s Early Experience.</article-title>
<source/><italic>JACC: Clinical Electrophysiology.</italic>
<year>2016</year>;<volume>2</volume>(<issue>3</issue>):<fpage>253</fpage>–<lpage>62</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jacep.2016.01.020</pub-id>
</mixed-citation>
</ref>
<ref id="ref-38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nademanee</surname><given-names>K</given-names></name><name><surname>Hocini</surname><given-names>M</given-names></name><name><surname>Haissaguerre</surname><given-names>M</given-names></name></person-group>:
<article-title>Epicardial substrate ablation for Brugada syndrome.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2017</year>;<volume>14</volume>(<issue>3</issue>):<fpage>457</fpage>–<lpage>61</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2016.12.001</pub-id>
<pub-id pub-id-type="pmid">27979714</pub-id></mixed-citation>
</ref>
<ref id="ref-39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Tung</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><etal></etal></person-group>:
<article-title>Characterization of the epicardial substrate for catheter ablation of Brugada syndrome.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2016</year>;<volume>13</volume>(<issue>11</issue>):<fpage>2151</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2016.07.025</pub-id>
<pub-id pub-id-type="pmid">27453126</pub-id></mixed-citation>
</ref>
<ref id="ref-40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Connolly</surname><given-names>SJ</given-names></name><name><surname>Dorian</surname><given-names>P</given-names></name><name><surname>Roberts</surname><given-names>RS</given-names></name><etal></etal></person-group>:
<article-title>Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.</article-title>
<source/><italic>JAMA.</italic>
<year>2006</year>;<volume>295</volume>(<issue>2</issue>):<fpage>165</fpage>–<lpage>71</lpage>.
<pub-id pub-id-type="doi">10.1001/jama.295.2.165</pub-id>
<pub-id pub-id-type="pmid">16403928</pub-id></mixed-citation>
</ref>
<ref id="ref-41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schleifer</surname><given-names>JW</given-names></name><name><surname>Sorajja</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>WK</given-names></name></person-group>:
<article-title>Advances in the pharmacologic treatment of ventricular arrhythmias.</article-title>
<source/><italic>Expert Opin Pharmacother.</italic>
<year>2015</year>;<volume>16</volume>(<issue>17</issue>):<fpage>2637</fpage>–<lpage>51</lpage>.
<pub-id pub-id-type="doi">10.1517/14656566.2015.1100170</pub-id>
<pub-id pub-id-type="pmid">26513538</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727737448">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kudenchuk</surname><given-names>PJ</given-names></name><name><surname>Brown</surname><given-names>SP</given-names></name><name><surname>Daya</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.</article-title>
<source/><italic>N Engl J Med.</italic>
<year>2016</year>;<volume>374</volume>(<issue>18</issue>):<fpage>1711</fpage>–<lpage>22</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa1514204</pub-id>
<pub-id pub-id-type="pmid">27043165</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726263935">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ortiz</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Arribas</surname><given-names>F</given-names></name><etal></etal></person-group>:
<article-title>Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study.</article-title>
<source/><italic>Eur Heart J.</italic>
<year>2017</year>;<volume>38</volume>(<issue>17</issue>):<fpage>1329</fpage>–<lpage>35</lpage>.
<pub-id pub-id-type="doi">10.1093/eurheartj/ehw230</pub-id>
<!--<pub-id pub-id-type="pmcid">5410924</pub-id>-->
<pub-id pub-id-type="pmid">27354046</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726470648">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sapp</surname><given-names>JL</given-names></name><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Parkash</surname><given-names>R</given-names></name><etal></etal></person-group>:
<article-title>Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.</article-title>
<source/><italic>N Engl J Med.</italic>
<year>2016</year>;<volume>375</volume>(<issue>2</issue>):<fpage>111</fpage>–<lpage>21</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa1513614</pub-id>
<pub-id pub-id-type="pmid">27149033</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726334804">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Santangeli</surname><given-names>P</given-names></name><etal></etal></person-group>:
<article-title>Amiodarone Discontinuation or Dose Reduction Following Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease.</article-title>
<source/><italic>JACC: Clinical Electrophysiology.</italic>
<year>2017</year>;<volume>3</volume>(<issue>5</issue>):<fpage>503</fpage>–<lpage>11</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jacep.2016.11.005</pub-id>
</mixed-citation>
</ref>
<ref id="ref-46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tagami</surname><given-names>T</given-names></name><name><surname>Matsui</surname><given-names>H</given-names></name><name><surname>Ishinokami</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest.</article-title>
<source/><italic>Resuscitation.</italic>
<year>2016</year>;<volume>109</volume>:<fpage>127</fpage>–<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.1016/j.resuscitation.2016.08.017</pub-id>
<pub-id pub-id-type="pmid">27568110</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726688697">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harayama</surname><given-names>N</given-names></name><name><surname>Nihei</surname><given-names>S</given-names></name><name><surname>Nagata</surname><given-names>K</given-names></name><etal></etal></person-group>:
<article-title>Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation.</article-title>
<source/><italic>J Anesth.</italic>
<year>2014</year>;<volume>28</volume>(<issue>4</issue>):<fpage>587</fpage>–<lpage>92</lpage>.
<pub-id pub-id-type="doi">10.1007/s00540-013-1775-5</pub-id>
<!--<pub-id pub-id-type="pmcid">4126999</pub-id>-->
<pub-id pub-id-type="pmid">24389941</pub-id></mixed-citation>
</ref>
<ref id="ref-48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dorian</surname><given-names>P</given-names></name><name><surname>Borggrefe</surname><given-names>M</given-names></name><name><surname>Al-Khalidi</surname><given-names>HR</given-names></name><etal></etal></person-group>:
<article-title>Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.</article-title>
<source/><italic>Circulation.</italic>
<year>2004</year>;<volume>110</volume>(<issue>24</issue>):<fpage>3646</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1161/01.CIR.0000149240.98971.A8</pub-id>
<pub-id pub-id-type="pmid">15533855</pub-id></mixed-citation>
</ref>
<ref id="ref-49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Køber</surname><given-names>L</given-names></name><name><surname>Thune</surname><given-names>JJ</given-names></name><name><surname>Nielsen</surname><given-names>JC</given-names></name><etal></etal></person-group>:
<article-title>Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.</article-title>
<source/><italic>N Engl J Med.</italic>
<year>2016</year>;<volume>375</volume>(<issue>13</issue>):<fpage>1221</fpage>–<lpage>30</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa1608029</pub-id>
<pub-id pub-id-type="pmid">27571011</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726683450">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilkoff</surname><given-names>BL</given-names></name><name><surname>Fauchier</surname><given-names>L</given-names></name><name><surname>Stiles</surname><given-names>MK</given-names></name><etal></etal></person-group>:
<article-title>2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2016</year>;<volume>13</volume>(<issue>2</issue>):<fpage>e50</fpage>–<lpage>86</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2015.11.018</pub-id>
<pub-id pub-id-type="pmid">26607062</pub-id></mixed-citation>
</ref>
<ref id="ref-51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lambiase</surname><given-names>PD</given-names></name><name><surname>Barr</surname><given-names>C</given-names></name><name><surname>Theuns</surname><given-names>DA</given-names></name><etal></etal></person-group>:
<article-title>Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry.</article-title>
<source/><italic>Eur Heart J.</italic>
<year>2014</year>;<volume>35</volume>(<issue>25</issue>):<fpage>1657</fpage>–<lpage>65</lpage>.
<pub-id pub-id-type="doi">10.1093/eurheartj/ehu112</pub-id>
<!--<pub-id pub-id-type="pmcid">4076663</pub-id>-->
<pub-id pub-id-type="pmid">24670710</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718326938">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burke</surname><given-names>MC</given-names></name><name><surname>Gold</surname><given-names>MR</given-names></name><name><surname>Knight</surname><given-names>BP</given-names></name><etal></etal></person-group>:
<article-title>Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry.</article-title>
<source/><italic>J Am Coll Cardiol.</italic>
<year>2015</year>;<volume>65</volume>(<issue>16</issue>):<fpage>1605</fpage>–<lpage>15</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jacc.2015.02.047</pub-id>
<pub-id pub-id-type="pmid">25908064</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727737449">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Mondésert</surname><given-names>B</given-names></name><name><surname>Lloyd</surname><given-names>MS</given-names></name><etal></etal></person-group>:
<article-title>Clinical Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Adults With Congenital Heart Disease.</article-title>
<source/><italic>Circ Arrhythm Electrophysiol.</italic>
<year>2016</year>;<volume>9</volume>(<issue>9</issue>): pii: e004338.
<pub-id pub-id-type="doi">10.1161/CIRCEP.116.004338</pub-id>
<pub-id pub-id-type="pmid">27635073</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726745339">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Maria</surname><given-names>E</given-names></name><name><surname>Cappelli</surname><given-names>S</given-names></name><name><surname>Cappato</surname><given-names>R</given-names></name></person-group>:
<article-title>Shock efficacy of the entirely subcutaneous defibrillator for termination of spontaneous ventricular fibrillation in Brugada syndrome.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2013</year>;<volume>10</volume>(<issue>12</issue>):<fpage>1807</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2013.08.008</pub-id>
<pub-id pub-id-type="pmid">23933298</pub-id></mixed-citation>
</ref>
<ref id="ref-55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maurizi</surname><given-names>N</given-names></name><name><surname>Tanini</surname><given-names>I</given-names></name><name><surname>Olivotto</surname><given-names>I</given-names></name><etal></etal></person-group>:
<article-title>Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy.</article-title>
<source/><italic>Int J Cardiol.</italic>
<year>2017</year>;<volume>231</volume>:<fpage>115</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ijcard.2016.12.187</pub-id>
<pub-id pub-id-type="pmid">28073660</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727737450">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gold</surname><given-names>MR</given-names></name><name><surname>Theuns</surname><given-names>DA</given-names></name><name><surname>Knight</surname><given-names>BP</given-names></name><etal></etal></person-group>:
<article-title>Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study.</article-title>
<source/><italic>J Cardiovasc Electrophysiol.</italic>
<year>2012</year>;<volume>23</volume>(<issue>4</issue>):<fpage>359</fpage>–<lpage>66</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1540-8167.2011.02199.x</pub-id>
<pub-id pub-id-type="pmid">22035049</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/722826652">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olde Nordkamp</surname><given-names>LR</given-names></name><name><surname>Knops</surname><given-names>RE</given-names></name><name><surname>Bardy</surname><given-names>GH</given-names></name><etal></etal></person-group>:
<article-title>Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy.</article-title>
<source/><italic>Am Heart J.</italic>
<year>2012</year>;<volume>163</volume>(<issue>5</issue>):<fpage>753</fpage>–<lpage>760.e2</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ahj.2012.02.012</pub-id>
<pub-id pub-id-type="pmid">22607851</pub-id></mixed-citation>
</ref>
<ref id="ref-58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gold</surname><given-names>MR</given-names></name><name><surname>Knops</surname><given-names>R</given-names></name><name><surname>Burke</surname><given-names>MC</given-names></name><etal></etal></person-group>:
<article-title>The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED).</article-title>
<source/><italic>Pacing Clin Electrophysiol.</italic>
<year>2017</year>;<volume>40</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1111/pace.12994</pub-id>
<pub-id pub-id-type="pmid">27943348</pub-id></mixed-citation>
</ref>
<ref id="ref-59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neuzil</surname><given-names>P</given-names></name><name><surname>Reddy</surname><given-names>VY</given-names></name><name><surname>Merkely</surname><given-names>B</given-names></name><etal></etal></person-group>:
<article-title>Implantable intravascular defibrillator: defibrillation thresholds of an intravascular cardioverter-defibrillator compared with those of a conventional ICD in humans.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2014</year>;<volume>11</volume>(<issue>2</issue>):<fpage>210</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2013.10.035</pub-id>
<pub-id pub-id-type="pmid">24144885</pub-id></mixed-citation>
</ref>
<ref id="ref-60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mallidi</surname><given-names>J</given-names></name><name><surname>Nadkarni</surname><given-names>GN</given-names></name><name><surname>Berger</surname><given-names>RD</given-names></name><etal></etal></person-group>:
<article-title>Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular tachycardia in patients with structural heart disease.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2011</year>;<volume>8</volume>(<issue>4</issue>):<fpage>503</fpage>–<lpage>10</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2010.12.015</pub-id>
<!--<pub-id pub-id-type="pmcid">3065522</pub-id>-->
<pub-id pub-id-type="pmid">21147263</pub-id></mixed-citation>
</ref>
<ref id="ref-61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pokorney</surname><given-names>SD</given-names></name><name><surname>Friedman</surname><given-names>DJ</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><etal></etal></person-group>:
<article-title>Catheter ablation of ventricular tachycardia: Lessons learned from past clinical trials and implications for future clinical trials.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2016</year>;<volume>13</volume>(<issue>8</issue>):<fpage>1748</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2016.04.001</pub-id>
<!--<pub-id pub-id-type="pmcid">5070490</pub-id>-->
<pub-id pub-id-type="pmid">27050910</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726268468">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>WG</given-names></name><name><surname>Soejima</surname><given-names>K</given-names></name></person-group>:
<article-title>Catheter ablation for ventricular tachycardia.</article-title>
<source/><italic>Circulation.</italic>
<year>2007</year>;<volume>115</volume>(<issue>21</issue>):<fpage>2750</fpage>–<lpage>60</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.655720</pub-id>
<pub-id pub-id-type="pmid">17533195</pub-id></mixed-citation>
</ref>
<ref id="ref-63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Proietti</surname><given-names>R</given-names></name><name><surname>Essebag</surname><given-names>V</given-names></name><name><surname>Beardsall</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome.</article-title>
<source/><italic>Europace.</italic>
<year>2015</year>;<volume>17</volume>(<issue>3</issue>):<fpage>461</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1093/europace/euu326</pub-id>
<pub-id pub-id-type="pmid">25488957</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725274025">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Biase</surname><given-names>L</given-names></name><name><surname>Burkhardt</surname><given-names>JD</given-names></name><name><surname>Lakkireddy</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy: The VISTA Randomized Multicenter Trial.</article-title>
<source/><italic>J Am Coll Cardiol.</italic>
<year>2015</year>;<volume>66</volume>(<issue>25</issue>):<fpage>2872</fpage>–<lpage>82</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jacc.2015.10.026</pub-id>
<pub-id pub-id-type="pmid">26718674</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726048123">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Romero</surname><given-names>J</given-names></name><name><surname>Mehta</surname><given-names>NK</given-names></name><etal></etal></person-group>:
<article-title>Long-term outcomes after catheter ablation of ventricular tachycardia in patients with and without structural heart disease.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2016</year>;<volume>13</volume>(<issue>10</issue>):<fpage>1957</fpage>–<lpage>63</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2016.07.001</pub-id>
<pub-id pub-id-type="pmid">27392945</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726491738">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tung</surname><given-names>R</given-names></name><name><surname>Vaseghi</surname><given-names>M</given-names></name><name><surname>Frankel</surname><given-names>DS</given-names></name><etal></etal></person-group>:
<article-title>Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2015</year>;<volume>12</volume>(<issue>9</issue>):<fpage>1997</fpage>–<lpage>2007</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2015.05.036</pub-id>
<!--<pub-id pub-id-type="pmcid">4549209</pub-id>-->
<pub-id pub-id-type="pmid">26031376</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725529692">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-67">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marchlinski</surname><given-names>FE</given-names></name><name><surname>Haffajee</surname><given-names>CI</given-names></name><name><surname>Beshai</surname><given-names>JF</given-names></name><etal></etal></person-group>:
<article-title>Long-Term Success of Irrigated Radiofrequency Catheter Ablation of Sustained Ventricular Tachycardia: Post-Approval THERMOCOOL VT Trial.</article-title>
<source/><italic>J Am Coll Cardiol.</italic>
<year>2016</year>;<volume>67</volume>(<issue>6</issue>):<fpage>674</fpage>–<lpage>83</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jacc.2015.11.041</pub-id>
<pub-id pub-id-type="pmid">26868693</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726148344">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-68">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>H</given-names></name><name><surname>Vergara</surname><given-names>P</given-names></name><name><surname>Maccabelli</surname><given-names>G</given-names></name><etal></etal></person-group>:
<article-title>Contact force monitoring for cardiac mapping in patients with ventricular tachycardia.</article-title>
<source/><italic>J Cardiovasc Electrophysiol.</italic>
<year>2013</year>;<volume>24</volume>(<issue>5</issue>):<fpage>519</fpage>–<lpage>24</lpage>.
<pub-id pub-id-type="doi">10.1111/jce.12080</pub-id>
<pub-id pub-id-type="pmid">23373693</pub-id></mixed-citation>
</ref>
<ref id="ref-69">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aryana</surname><given-names>A</given-names></name><name><surname>d'Avila</surname><given-names>A</given-names></name></person-group>:
<article-title>Contact force during VT ablation: vector orientation is key.</article-title>
<source/><italic>Circ Arrhythm Electrophysiol.</italic>
<year>2014</year>;<volume>7</volume>(<issue>6</issue>):<fpage>1009</fpage>–<lpage>10</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCEP.114.002389</pub-id>
<pub-id pub-id-type="pmid">25516578</pub-id></mixed-citation>
</ref>
<ref id="ref-70">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jesel</surname><given-names>L</given-names></name><name><surname>Sacher</surname><given-names>F</given-names></name><name><surname>Komatsu</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>Characterization of contact force during endocardial and epicardial ventricular mapping.</article-title>
<source/><italic>Circ Arrhythm Electrophysiol.</italic>
<year>2014</year>;<volume>7</volume>(<issue>6</issue>):<fpage>1168</fpage>–<lpage>73</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCEP.113.001219</pub-id>
<pub-id pub-id-type="pmid">25258362</pub-id></mixed-citation>
</ref>
<ref id="ref-71">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Almendral</surname><given-names>J</given-names></name><name><surname>Castellanos</surname><given-names>E</given-names></name></person-group>:
<article-title>Epicardial ablation in post-myocardial infarction ventricular tachycardia: could it be one of the missing pieces of the puzzle?</article-title>
<source/><italic>Circ Arrhythm Electrophysiol.</italic>
<year>2015</year>;<volume>8</volume>(<issue>4</issue>):<fpage>767</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCEP.115.003247</pub-id>
<pub-id pub-id-type="pmid">26286302</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727737520">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-72">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aryana</surname><given-names>A</given-names></name><name><surname>d'Avila</surname><given-names>A</given-names></name></person-group>:
<article-title>Epicardial Catheter Ablation of Ventricular Tachycardia.</article-title>
<source/><italic>Card Electrophysiol Clin.</italic>
<year>2017</year>;<volume>9</volume>(<issue>1</issue>):<fpage>119</fpage>–<lpage>31</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ccep.2016.10.009</pub-id>
<pub-id pub-id-type="pmid">28167080</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727737521">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-73">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sauer</surname><given-names>WH</given-names></name><name><surname>Steckman</surname><given-names>DA</given-names></name><name><surname>Zipse</surname><given-names>MM</given-names></name><etal></etal></person-group>:
<article-title>High-power bipolar ablation for incessant ventricular tachycardia utilizing a deep midmyocardial septal circuit.</article-title>
<source/><italic>HeartRhythm Case Rep.</italic>
<year>2015</year>;<volume>1</volume>(<issue>6</issue>):<fpage>397</fpage>–<lpage>400</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrcr.2015.01.018</pub-id>
<!--<pub-id pub-id-type="pmcid">5419695</pub-id>-->
<pub-id pub-id-type="pmid">28491595</pub-id></mixed-citation>
</ref>
<ref id="ref-74">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koruth</surname><given-names>JS</given-names></name><name><surname>Dukkipati</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>MA</given-names></name><etal></etal></person-group>:
<article-title>Bipolar irrigated radiofrequency ablation: a therapeutic option for refractory intramural atrial and ventricular tachycardia circuits.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2012</year>;<volume>9</volume>(<issue>12</issue>):<fpage>1932</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2012.08.001</pub-id>
<pub-id pub-id-type="pmid">22863684</pub-id></mixed-citation>
</ref>
<ref id="ref-75">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skoda</surname><given-names>J</given-names></name><name><surname>Arya</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>F</given-names></name><etal></etal></person-group>:
<article-title>Catheter Ablation of Ischemic Ventricular Tachycardia With Remote Magnetic Navigation: STOP-VT Multicenter Trial.</article-title>
<source/><italic>J Cardiovasc Electrophysiol.</italic>
<year>2016</year>;<volume>27</volume>(<issue>Suppl 1</issue>):<fpage>S29</fpage>–<lpage>37</lpage>.
<pub-id pub-id-type="doi">10.1111/jce.12910</pub-id>
<pub-id pub-id-type="pmid">26969220</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726214016">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-76">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>EK</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>KY</given-names></name><etal></etal></person-group>:
<article-title>Surgical cryoablation for ventricular tachyarrhythmia arising from the left ventricular outflow tract region.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2015</year>;<volume>12</volume>(<issue>6</issue>):<fpage>1128</fpage>–<lpage>36</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2015.02.016</pub-id>
<pub-id pub-id-type="pmid">25697752</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725364880">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-77">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sapp</surname><given-names>JL</given-names></name><name><surname>Beeckler</surname><given-names>C</given-names></name><name><surname>Pike</surname><given-names>R</given-names></name><etal></etal></person-group>:
<article-title>Initial human feasibility of infusion needle catheter ablation for refractory ventricular tachycardia.</article-title>
<source/><italic>Circulation.</italic>
<year>2013</year>;<volume>128</volume>(<issue>21</issue>):<fpage>2289</fpage>–<lpage>95</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.003423</pub-id>
<pub-id pub-id-type="pmid">24036605</pub-id></mixed-citation>
</ref>
<ref id="ref-78">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gianni</surname><given-names>C</given-names></name><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Trivedi</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Alternative Approaches for Ablation of Resistant Ventricular Tachycardia.</article-title>
<source/><italic>Card Electrophysiol Clin.</italic>
<year>2017</year>;<volume>9</volume>(<issue>1</issue>):<fpage>93</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ccep.2016.10.006</pub-id>
<pub-id pub-id-type="pmid">28167089</pub-id></mixed-citation>
</ref>
<ref id="ref-79">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Philips</surname><given-names>B</given-names></name><name><surname>te Riele</surname><given-names>AS</given-names></name><name><surname>Sawant</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2015</year>;<volume>12</volume>(<issue>4</issue>):<fpage>716</fpage>–<lpage>25</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2014.12.018</pub-id>
<pub-id pub-id-type="pmid">25530221</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725286975">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-80">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hong</surname><given-names>JC</given-names></name><name><surname>Crawford</surname><given-names>T</given-names></name><name><surname>Tandri</surname><given-names>H</given-names></name><etal></etal></person-group>:
<article-title>What Is the Role of Cardiac Sympathetic Denervation for Recurrent Ventricular Tachycardia?</article-title>
<source/><italic>Curr Treat Options Cardiovasc Med.</italic>
<year>2017</year>;<volume>19</volume>(<issue>2</issue>):<fpage>11</fpage>.
<pub-id pub-id-type="doi">10.1007/s11936-017-0512-z</pub-id>
<pub-id pub-id-type="pmid">28275941</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727737522">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-81">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tan</surname><given-names>AY</given-names></name><name><surname>Abdi</surname><given-names>S</given-names></name><name><surname>Buxton</surname><given-names>AE</given-names></name><etal></etal></person-group>:
<article-title>Percutaneous stellate ganglia block for acute control of refractory ventricular tachycardia.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2012</year>;<volume>9</volume>(<issue>12</issue>):<fpage>2063</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2012.07.030</pub-id>
<pub-id pub-id-type="pmid">22863887</pub-id></mixed-citation>
</ref>
<ref id="ref-82">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vaseghi</surname><given-names>M</given-names></name><name><surname>Gima</surname><given-names>J</given-names></name><name><surname>Kanaan</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up.</article-title>
<source/><italic>Heart Rhythm.</italic>
<year>2014</year>;<volume>11</volume>(<issue>3</issue>):<fpage>360</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1016/j.hrthm.2013.11.028</pub-id>
<!--<pub-id pub-id-type="pmcid">4253031</pub-id>-->
<pub-id pub-id-type="pmid">24291775</pub-id></mixed-citation>
</ref>
<ref id="ref-83">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cuculich</surname><given-names>P</given-names></name></person-group>(Principal Investigator):
<article-title>Phase I/II Study of EP-guided Noninvasive cardiac radioablation for treatment of ventricular tachycardia (ENCORE-VT)</article-title>.
<italic>Clinicaltrials.gov</italic> NCT02919618.
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02919618">Reference Source</ext-link>
</mixed-citation>
</ref>
<ref id="ref-84">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loo</surname><given-names>BW</given-names><suffix>Jr</suffix></name><name><surname>Soltys</surname><given-names>SG</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia.</article-title>
<source/><italic>Circ Arrhythm Electrophysiol.</italic>
<year>2015</year>;<volume>8</volume>(<issue>3</issue>):<fpage>748</fpage>–<lpage>50</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCEP.115.002765</pub-id>
<pub-id pub-id-type="pmid">26082532</pub-id></mixed-citation>
</ref>
<ref id="ref-85">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maguire</surname><given-names>P</given-names></name></person-group>:
<article-title>CyberHeart’s Cardiac arrhythmia ablation treatment: patients with refractory ventricular tachycardia/fibrillation</article-title>.
<italic>Clinicaltrials.gov</italic> NCT02661048.
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02661048">Reference Source</ext-link>
</mixed-citation>
</ref>
<ref id="ref-86">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>WG</given-names></name></person-group>:
<article-title>Intramural needle ablation for ablation of recurrent ventricular tachycardia</article-title>.
<italic>Clinicaltrials.gov</italic> NCT01791543.
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01791543">Reference Source</ext-link>
</mixed-citation>
</ref>
<ref id="ref-87">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>DT</given-names></name><name><surname>Tzou</surname><given-names>WS</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>Enhanced Radiofrequency Ablation With Magnetically Directed Metallic Nanoparticles.</article-title>
<source/><italic>Circ Arrhythm Electrophysiol.</italic>
<year>2016</year>;<volume>9</volume>(<issue>5</issue>): pii: e003820.
<pub-id pub-id-type="doi">10.1161/CIRCEP.115.003820</pub-id>
<pub-id pub-id-type="pmid">27162034</pub-id></mixed-citation>
</ref>
<ref id="ref-88">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klein</surname><given-names>T</given-names></name><name><surname>Abdulghani</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Three-dimensional 123I-meta-iodobenzylguanidine cardiac innervation maps to assess substrate and successful ablation sites for ventricular tachycardia: feasibility study for a novel paradigm of innervation imaging.</article-title>
<source/><italic>Circ Arrhythm Electrophysiol.</italic>
<year>2015</year>;<volume>8</volume>(<issue>3</issue>):<fpage>583</fpage>–<lpage>91</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCEP.114.002105</pub-id>
<pub-id pub-id-type="pmid">25713216</pub-id></mixed-citation>
</ref>
<ref id="ref-89">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>AF</given-names></name><name><surname>Senior</surname><given-names>R</given-names></name><name><surname>Cerqueira</surname><given-names>MD</given-names></name><etal></etal></person-group>:
<article-title>Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study.</article-title>
<source/><italic>J Am Coll Cardiol.</italic>
<year>2010</year>;<volume>55</volume>(<issue>20</issue>):<fpage>2212</fpage>–<lpage>21</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jacc.2010.01.014</pub-id>
<pub-id pub-id-type="pmid">20188504</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/3882956">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-90">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oster</surname><given-names>HS</given-names></name><name><surname>Taccardi</surname><given-names>B</given-names></name><name><surname>Lux</surname><given-names>RL</given-names></name><etal></etal></person-group>:
<article-title>Electrocardiographic imaging: Noninvasive characterization of intramural myocardial activation from inverse-reconstructed epicardial potentials and electrograms.</article-title>
<source/><italic>Circulation.</italic>
<year>1998</year>;<volume>97</volume>(<issue>15</issue>):<fpage>1496</fpage>–<lpage>507</lpage>.
<pub-id pub-id-type="doi">10.1161/01.CIR.97.15.1496</pub-id>
<pub-id pub-id-type="pmid">9576431</pub-id></mixed-citation>
</ref>
<ref id="ref-91">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Sacher</surname><given-names>F</given-names></name><name><surname>Hoffmayer</surname><given-names>K</given-names></name><etal></etal></person-group>:
<article-title>Cardiac electrophysiological substrate underlying the ECG phenotype and electrogram abnormalities in Brugada syndrome patients.</article-title>
<source/><italic>Circulation.</italic>
<year>2015</year>;<volume>131</volume>(<issue>22</issue>):<fpage>1950</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.013698</pub-id>
<!--<pub-id pub-id-type="pmcid">4452400</pub-id>-->
<pub-id pub-id-type="pmid">25810336</pub-id></mixed-citation>
</ref>
<ref id="ref-92">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>DH</given-names></name><name><surname>Desouza</surname><given-names>KA</given-names></name><etal></etal></person-group>:
<article-title>Electrophysiologic Scar Substrate in Relation to VT: Noninvasive High-Resolution Mapping and Risk Assessment with ECGI.</article-title>
<source/><italic>Pacing Clin Electrophysiol.</italic>
<year>2016</year>;<volume>39</volume>(<issue>8</issue>):<fpage>781</fpage>–<lpage>91</lpage>.
<pub-id pub-id-type="doi">10.1111/pace.12882</pub-id>
<!--<pub-id pub-id-type="pmcid">4970912</pub-id>-->
<pub-id pub-id-type="pmid">27197804</pub-id></mixed-citation>
</ref>
<ref id="ref-93">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luther</surname><given-names>V</given-names></name><name><surname>Linton</surname><given-names>NW</given-names></name><name><surname>Jamil-Copley</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>A Prospective Study of Ripple Mapping the Post-Infarct Ventricular Scar to Guide Substrate Ablation for Ventricular Tachycardia.</article-title>
<source/><italic>Circ Arrhythm Electrophysiol.</italic>
<year>2016</year>;<volume>9</volume>(<issue>6</issue>): pii: e004072.
<pub-id pub-id-type="doi">10.1161/CIRCEP.116.004072</pub-id>
<pub-id pub-id-type="pmid">27307519</pub-id></mixed-citation>
</ref>
<ref id="ref-94">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jamil-Copley</surname><given-names>S</given-names></name><name><surname>Vergara</surname><given-names>P</given-names></name><name><surname>Carbucicchio</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Application of ripple mapping to visualize slow conduction channels within the infarct-related left ventricular scar.</article-title>
<source/><italic>Circ Arrhythm Electrophysiol.</italic>
<year>2015</year>;<volume>8</volume>(<issue>1</issue>):<fpage>76</fpage>–<lpage>86</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCEP.114.001827</pub-id>
<pub-id pub-id-type="pmid">25527678</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>